Connect with us

Hi, what are you looking for?

Business

U.S. to buy 300,000 doses of Eli Lilly coronavirus antibody drug

The U.S. drug-maker said the company would start delivering the 300,000 doses of its experimental antibody treatment drug over a two-month period, as soon as it gets its authorization for emergency use from the Food and Drug Administration (FDA).

The treatment, bamlanivimab, is the same one that the National Institute of Allergy and Infectious Diseases (NIAID) halted a study on Monday, citing data that suggested it was “unlikely” to help hospitalized patients recover from the virus.

However, on Monday, Eli Lilly said that all other studies of its monoclonal antibody drug, bamlanivimab, will continue, including one in recently diagnosed COVID-19 patients with mild to moderate symptoms and another in people at risk of infection

This study is what the company submitted a request to the U.S. Food and Drug Administration earlier this month for emergency use authorization of the drug to treat mild to moderate COVID-19 patients, reports Reuters.

Lilly’s antibody therapy is similar to a drug from Regeneron that was given to Trump during his bout with COVID-19. The treatment uses monoclonal antibodies, which are made to act as immune cells in the human body. And even though Trump said his Regeneron treatment was a “cure,” data shows antibody drugs are indeed promising, however, medical experts say it’s far from a cure as trials are still needed to determine how well it works, reports CNBC.

The cost per dose of Lilly’s treatment amounts to $1,250 as per the contract, however, patients will not have to pay for the medicine, according to Business Insider.

Lilly, in a statement, said “patients will have no out-of-pocket costs for the medicine,” although healthcare facilities may charge a fee for the administration of the treatment.

Avatar photo
Written By

We are deeply saddened to announce the passing of our dear friend Karen Graham, who served as Editor-at-Large at Digital Journal. She was 78 years old. Karen's view of what is happening in our world was colored by her love of history and how the past influences events taking place today. Her belief in humankind's part in the care of the planet and our environment has led her to focus on the need for action in dealing with climate change. It was said by Geoffrey C. Ward, "Journalism is merely history's first draft." Everyone who writes about what is happening today is indeed, writing a small part of our history.

You may also like:

Tech & Science

Under new legislation that passed the House of Representatives last week, TikTok could be banned in the United States.

Social Media

Wanna buy some ignorance? You’re in luck.

Life

Platforms like Instagram and Pinterest often suggest travel destinations based on your likes and viewing habits.

Business

United Airlines CEO Scott Kirby said the carrier was reviewing recent incidents and would redouble safety initiatives as needed - Copyright AFP Logan CyrusUnited...